From Wikipedia, the free encyclopedia
2F-QMPSB structure.png
Legal status
Legal status
  • 8-quinolinyl 4-methyl-3-[(4,4-difluoropiperidin-1-yl)sulfonyl]benzoate
PubChem CID
Chemical and physical data
Molar mass446.467 g·mol−1
3D model (JSmol)
  • FC1(F)CCN(CC1)S(=O)(=O)c2cc(ccc2C)C(=O)Oc4cccc3cccnc34
  • InChI=1S/C22H20F2N2O4S/c1-15-7-8-17(14-19(15)31(28,29)26-12-9-22(23,24)10-13-26)21(27)30-18-6-2-4-16-5-3-11-25-20(16)18/h2-8,11,14H,9-10,12-13H2,1H3

2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug.[1] Its identification was first reported by a forensic laboratory in Italy in January 2019,[2] and it was made illegal in Latvia shortly afterwards.[3][4] Fluorination of the tail group is a common strategy to increase potency at cannabinoid receptors which is seen in many related series of compounds.[5][6]

See also[edit]


  1. ^ Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C (2021). "Identification and Analytical Characterization of a Novel Synthetic Cannabinoid-Type Substance in Herbal Material in Europe". Molecules. 26 (4): 793. doi:10.3390/molecules26040793. PMC 7913736. PMID 33546439.
  2. ^ "NPS2019". Belgian Early Warning System on Drugs (BEWSD).
  3. ^ Centre for Disease Prevention and Control (17 January 2019). "Par aizlieguma noteikšanu vielai 2F-QMPSB un tās saturošiem izstrādājumiem" [On the Prohibition of 2F-QMPSB and Articles Containing It]. Latvian Journal: Legal Acts of the Republic of Latvia (in Latvian).
  4. ^ "Уважаемые эксперты" [Dear experts]. Aipsin Drugs (in Russian).
  5. ^ Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, et al. (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
  6. ^ Yang SW, Smotryski J, Matasi J, Ho G, Tulshian D, Greenlee WJ, et al. (January 2011). "Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain". Bioorganic & Medicinal Chemistry Letters. 21 (1): 182–5. doi:10.1016/j.bmcl.2010.11.044. PMID 21115245.